PMCB

3.97512.83%
ML

Matthias Löhr

Chairman of Medical & Scientific Advisory Board

Prof. Dr. Matthias Löhr, Ph.D. serves as the Managing Director at LB GmbH. He serves as a Consultant to PharmaCyte Biotech, Inc. in connection with its development of treatments for pancreatic cancer and diabetes based on the Cell-in-a-Box technology. He has expertise in the treatment of both diseases along with understanding the Cell-in-a-Box technology and its use in a clinical setting. Dr. Löhr served as the Chairman of Medical and Scientific Advisory Board at PharmaCyte Biotech, Inc. since October 2014 until March 31, 2022 and served as its Independent Director since March 31, 2022 until 2022 and serves as its Chairman of Medical and Scientific Advisory Board since 2022. He is a Full Professor of gastroenterology and hepatology at famed Karolinska Institute Institute in Stockholm, Sweden, and leads the Pancreatic Team at Karolinska University Hospital since 2007. He is a Clinical Consultant of pancreatic cancer and Professor of Gastroenterology at the University of Heidelberg with a same-named Unit at the German Cancer Research Center in Heidelberg, Germany. He was an Advisor at dievini Hopp BioTech holding GmbH & Co. KG. At the firm, he managed the clinical and scientific due diligence tasks associated with investment opportunities and is also involved in the evaluation of clinical studies. He is a Member of Clinical Cooperation Unit Molecular Gastroenterology, German Cancer Research Centre. Dr. Löhr served as an Advisor of Axcentua Pharmaceuticals AB. He served as an Advisor of Biocompatibles International plc. Since 2000, Dr. Löhr served as Professor of Molecular Gastroenterology at the University of Heidelberg and Head of a division at the German Cancer Research Center (DKFZ). He has expertise in the treatment of both diseases, in addition to thoroughly understanding PharmaCyte’s technology and its use in a clinical setting. He has also worked as a translational scientist and Principal Investigator in clinical studies in GI oncology for many years and served as the Principal Investigator for the Phase 1/2 and Phase 2 clinical trials of PharmaCyte’s pancreatic cancer treatment that were completed in the early 2000s. In addition to being highly published, he has extensive scientific and grant review experience, and he has received multiple awards and distinctions. He is a licensed physician and board-certified internist and gastroenterologist. He has a subspeciality in GI Oncology. He is also a Fellow of the European Board of Gastroenterology (FEBG) and a Fellow of the American Gastroenterology Association (AGAF). Dr. Löhr completed a postdoctoral fellowship at the Scripps Clinic & Research Foundation. He completed his M.D. thesis and residency in pathology and residency in internal medicine and gastroenterology in Erlangen and Rostock and also became Assistant Professor. Dr. Löhr holds a BA in Anthropology & Theology from the University of Kiel in Kiel, Germany, and MD and PhD degrees from the Universities of Hamburg and Rostock. Dr. Löhr holds a Ph.D. and an M.D. from Karolinska University Hospital, Stockholm, Sweden. Following receipt of his medical degree, he served a residency in pathology in Hamburg, Germany, and residencies in internal medicine and gastroenterology in Erlangen and Rostock, Germany, where he became chief resident and later attending physician and assistant professor at the University of Rostock. Dr. Löhr has also completed a postdoctoral fellowship at the Scripps Clinic & Research Foundation in La Jolla, California.

Positions